Report contents
Industry landscape
Where the company competes: narrow drug markets, drawn by patent and payer
Pfizer today is close to a pure branded biopharma company. It folded its off-patent business, Upjohn, into Viatris in 2020 and exited consumer health when Haleon was spun off in 2022, leaving two things: patented prescription medicines and vaccines, and a smaller contract-manufacturing arm, Pfizer CentreOne. The market that matters is not "pharma" in the aggregate. It is a set of molecule-level markets, each bounded by an approved indication, a patent clock and a payer's formulary. Pfizer's 2025 10-K organizes the business accordingly, with a competition section and a separate discussion of pricing pressure from managed care organizations.
Margin gets captured at the patent, not in the channel. Upstream sits discovery, clinical trials and manufacturing of drug substance and finished vials; downstream sit the distributors and payers who decide whether a prescription gets filled. Bargaining power shifts downstream the moment a drug is approved: three wholesalers (McKesson, Cencora and Cardinal Health) move most US drug volume, and three pharmacy benefit managers (Express Scripts, CVS Caremark and Optum Rx) control formulary placement for a large share of American prescriptions. The profit, though, stays upstream during exclusivity. Once that ends, the economics migrate to generic and biosimilar makers, and Pfizer either defends the franchise with a follow-on product or watches the revenue drain. Manufacturing scale and global regulatory reach are genuine assets in this chain. They lower cost and speed approval; they do not confer pricing power.
Geography reinforces the fragmentation. Patents, prices and reimbursement are national, so the same molecule is a different business in the United States, Germany, Japan and China, with separate filings and separate negotiations. The US carries the most weight because it is the only large market where prices are set mainly through private negotiation. That is also why Medicare's new statutory price negotiation is a structural change rather than a cyclical one. Eliquis, Pfizer's anticoagulant shared with Bristol Myers Squibb, was in the first tranche of ten drugs, and the negotiated prices took effect January 1, 2026.
| Arena | Pfizer products | Main rivals |
|---|---|---|
| Pneumococcal and RSV vaccines | Prevnar, Abrysvo | Merck (Capvaxive), GSK (Arexvy), Moderna (mResvia) |
| COVID-19 | Comirnaty (with BioNTech), Paxlovid | Moderna, Novavax |
| Oral anticoagulation | Eliquis (with Bristol Myers Squibb) | Bayer and J&J (Xarelto), Boehringer (Pradaxa), Daiichi Sankyo (Savaysa) |
| ATTR cardiac amyloidosis | Vyndaqel, Vyndamax | BridgeBio (Attruby), Alnylam (Amvuttra) |
| Antibody-drug conjugates in oncology | Adcetris, Padcev, Tivdak | Daiichi Sankyo and AstraZeneca, Gilead, Roche |
| Immunology | Xeljanz, Cibinqo, Velsipity | AbbVie (Rinvoq), Lilly (Olumiant) |
Rival shares in most of these arenas are not published on a comparable basis, so the table names the sellers rather than percentages.
Concentration is high per molecule and low at the company level. Three to five meaningful sellers typically compete in any one of these arenas, which is the practical definition of a tight market. Count rivals across the whole portfolio, though, and Pfizer faces a dozen large companies: Merck, AbbVie, J&J, Roche, Novartis, AstraZeneca, Sanofi, GSK, Bristol Myers Squibb, Eli Lilly, Amgen and Moderna. Entry barriers are high in the specific technical sense: a new drug takes roughly a decade and, by common industry estimates, well over $1 billion to reach approval, against a 20-year patent term layered with regulatory exclusivity of five years in the US for a new chemical entity and 12 for a biologic, plus manufacturing standards that regulators audit. Those barriers are real, and they are what keep the number of sellers per arena small.
The weakness is that such barriers protect the therapeutic class, not the seller holding it. Patent protection prevents copies of Pfizer's molecule; it does nothing to stop a better molecule. Merck's Capvaxive competes directly with Prevnar, and Alnylam's Amvuttra and BridgeBio's Attruby reached the ATTR market while Vyndaqel was still on patent. Each new entrant gives payers a substitute to bargain with, which is why Pfizer's own filing flags managed-care pricing pressure and government price constraints as persistent features of the business rather than temporary headwinds.
So the structural picture is a portfolio of staggered, time-limited monopolies, each sold country by country into a buyer base that has been consolidating for two decades. Whether Pfizer's breadth in vaccines and antibody-drug conjugates amounts to something more durable than a sequence of expiring franchises, or merely a longer queue of the same cliff, is the question the moat assessment turns on.
Competitive advantage
Does the company have a moat? Yes, a narrow one that deal prices consume
Overall rating: Moderate. Pfizer sells a portfolio of legal monopolies, each with an expiry date printed on the label. The barrier is real: while a patent runs, no pharmacist can substitute a copy, and a gross margin above 70% follows. What holds the rating at Moderate is a number that never appears on the income statement. Pfizer carried $71.26 billion of goodwill against $86.48 billion of equity at December 31, 2025, largely the price paid for pipeline it chose to buy. On total invested capital, estimated after-tax ROIC was about 9.2% in FY2025 and 7.8% in FY2024. Excluding goodwill, the same operating business earns roughly 17.5% on the capital actually working inside it (estimated). The drugs are well protected; the owner's return is about half what the drugs earn, because Pfizer handed the difference to the sellers of Seagen and its predecessors.
Concentration supports branded pharma as a whole, which is why a fat gross margin proves little about Pfizer specifically. Three to five sellers typically hold each arena it competes in, and a new entrant needs a decade of trials and a regulator's approval before it earns a dollar. Those barriers keep gross profit high; they do not keep revenue from falling when a patent lapses. Revenue went from $101.17 billion in FY2022 to $62.58 billion in FY2025, and free cash flow from $26.03 billion to $9.08 billion. Some of that decline was the COVID windfall unwinding, so the cliff and the windfall have to be separated before judging durability.
Market position: Fairly Strong, an incumbent in several arenas
Pfizer holds the incumbent product in most of its main markets: Prevnar in pneumococcal vaccines, Eliquis in oral anticoagulation (shared with Bristol Myers Squibb), Vyndaqel in ATTR cardiac amyloidosis, plus a position in antibody-drug conjugates acquired with Seagen. Incumbency carries weight here because displacing an approved drug usually requires a trial showing it is better, not merely equivalent, and payers rarely switch without one. Pfizer is one of the largest drugmakers in the world by revenue, but size spread across many arenas is not the same as share in any single one, and no public series tracks its position across these markets on a consistent basis. First tier, without demonstrable dominance, is what the record supports.
Stability: Moderate, the base has stopped shrinking but the cliff is ahead
Five-year share stability cannot be confirmed on comparable measures. What the financials show is a base that fell hard and then flattened: revenue of $59.55 billion in FY2023, $63.63 billion in FY2024 and $62.58 billion in FY2025. The first nine months of 2026 produced $46.06 billion against $45.01 billion a year earlier, up 2.3%, so the top line has stopped eroding. Operating income moved the other way over the same nine months, to $11.48 billion from $13.72 billion. The scheduled test is close: Morningstar expects generic competition for Eliquis, Ibrance and Vyndaqel in 2027-28 and estimates expirations covering more than a quarter of 2024 revenue by 2028. That is a documented erosion calendar, not a hypothetical.
Returns: Moderate, about 9% on invested capital
For FY2025, operating income of $17.41 billion taxed at the 21% US statutory rate gives NOPAT of roughly $13.75 billion (estimated). The reported provision was a small net benefit, so a normalized rate is the cleaner base. Invested capital was equity of $86.48 billion plus total debt of $64.29 billion less cash of $1.14 billion, or $149.63 billion. That yields 9.2%. The same arithmetic on FY2024 gives 7.8%, and annualizing the first nine months of 2026 gives about 8.1% on invested capital of $149.85 billion at September 30, 2026. The benchmark for a clear advantage is 15%-25% sustained; 6%-8% usually signals none. Pfizer sits in the gap, one to two points above the 7.1% cost of capital Morningstar estimates. Leverage is not flattering the picture either: ROE was 8.9% in FY2025 on $62.67 billion of debt.
Margins: Moderate, a category margin rather than a Pfizer premium
Gross margin was 74.3% in FY2025 and 75.7% in the third quarter of 2026, against 58.1% in FY2023, when COVID inventory charges and a weak Paxlovid year distorted the base. Net margin was 12.4% in FY2025 on $7.77 billion of net income, versus 12.6% in FY2024 and 31.0% in FY2022. The gross line reflects what patented medicines earn as a class; the net line shows how much of it goes to research, amortization of acquired intangibles and $2.67 billion of interest. Scale helps spread those fixed costs across $62.58 billion of revenue, but it is a prerequisite for the economics, not proof of pricing power.
Overall rating: Moderate
Market position is Fairly Strong and stability Moderate, but profitability carries the most weight and it is only Moderate on a total-capital basis. The barrier is legal and certain for each molecule; the excess return it throws off is thin enough that Morningstar cut its moat rating from wide to narrow in July 2025. The gap between the sub-ratings and the overall call is the goodwill: what Pfizer's products earn and what Pfizer's shareholders keep are two different numbers.
Where the advantage comes from and how long it can last: about one patent cycle
Three sources matter, and they are not equal. Patent exclusivity does the protecting, prescriber habit adds a little, and scale converts the first two into a commercial operation. The metric that most directly tests the moat is the spread between ROIC and the cost of capital; the metric that predicts where it goes next is the share of revenue losing exclusivity within three years, which Morningstar puts above a quarter of 2024 revenue by 2028.
Patents: Fairly Strong, and the clock runs per molecule
Patent protection is the strongest source and the easiest to date. During exclusivity the customer cannot leave: a pharmacy has no generic to substitute, and a physician who wants to switch must prescribe a rival's molecule and win payer approval for it. The barrier is legal, so it does not depend on Pfizer's execution, and it shows up in the 74.3% gross margin reported for FY2025. Rivals can still take the market with a different molecule, which is why the protection is per-product: Merck's Capvaxive competes with Prevnar, and BridgeBio's Attruby and Alnylam's Amvuttra reached the ATTR market while Vyndaqel was still on patent. An approved alternative hands payers a substitute to price against, so pricing power in that indication weakens before the patent ever lapses. The scheduled break comes in 2027-28 with Eliquis, Ibrance and Vyndaqel. The open question is not whether Pfizer loses the legal monopoly, which is certain, but how much revenue survives it; a follow-on formulation, a six-month pediatric extension or a switch to a new mechanism can hold part of a franchise. The adverse outcome to follow is post-expiry revenue retention on Eliquis after 2028.
Prescriber habit: Weak, with vaccines the exception
Patients do not choose molecules; physicians write and payers pay, and that split limits captivity. Habit exists: a clinician who knows a drug's tolerability hesitates to change, hospital formulary approval takes months, and prior authorization paperwork discourages switching. None of that survives a competitor with better data and a better net price. The practical test is whether a rival's discount fails to take share, and Pfizer fails it wherever a substitute exists; Vyndaqel lost ground to new entrants while still patented, and the managed-care pricing pressure described in the company's 2025 10-K is the same force in slower motion. Vaccines are the partial exception. A product written into national immunization schedules and pediatric dosing series is hard to displace because switching a population-level program carries clinical and logistical risk, which is why Prevnar's franchise has lasted longer than a small-molecule patent cycle. That is captivity of a sort, but it is institutional, not personal, and it did not stop Capvaxive from entering. What would break it: a payer-driven shift in vaccine preference, or a rival regimen that cuts the number of doses.
Scale: Moderate, and useful mainly where patents hold the customer
Drug development carries large fixed costs. A late-stage cardiovascular or oncology program costs about the same to run for a company with $10 billion of revenue as for one with $60 billion, so the larger firm spreads the same spending over a wider base and can fund more attempts. Pfizer's revenue supports a commercial presence in most major markets and the manufacturing depth that vaccine production in particular requires. The limit is that scale protects only relative to a specific market, and Pfizer's consolidated size spans a dozen arenas where focused rivals can match it locally. In antibody-drug conjugates, the Seagen technology that justified the acquisition is being matched by Daiichi Sankyo and AstraZeneca, which is what learning by rivals looks like. What would break the scale argument is failed conversion: Morningstar forecasts $7.7 billion of Seagen revenue by 2030 against management's $10 billion goal.
Durability: real protection, roughly the length of the current pipeline
The pattern is old. Pfizer bought Warner-Lambert in 2000 largely for Lipitor, then bought Wyeth in 2009 ahead of Lipitor's 2011 US expiry. The moat protected the product; the company had to buy the next one, and the price it paid absorbed part of the profit it was buying. That is why the goodwill line matters more than the gross margin. Brand recognition is a false moat here, since patients rarely choose their own molecule. Access to capital is a false moat, since every large rival has it. Manufacturing or technology know-how is an operating edge that rivals learn. The real assets are the patents in force, the vaccine positions that outlast a typical small-molecule cycle, and the balance sheet that funds replacement. So far the evidence shows a moat that is genuine and finite: it should hold through the current exclusivity runway, and whether it extends past 2028 depends on pipeline output that has not yet been demonstrated.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow Pfizer Inc compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Pfizer Inc
Pfizer Inc
Business, moat and key questions
Open company page